Danirixin, another selective CXCR2 antagonist with high affinity, is able to effectively inhibit the binding of CXCL8 (IL‐8) to CXCR2, and several clinical trials have focused on its improvement of lung function in patients with mild to severe COPD (NCT03136380, NCT03250689, NCT03034967, and NCT02130193). The gene discussed is CXCL8; the disease is chronic obstructive pulmonary disease.